How Investors May Respond To Neuren Pharmaceuticals (ASX:NEU) 2025 Results, Buy-Back Plan And Pipeline Progress

Simply Wall St.03-02 15:13

Neuren Pharmaceuticals recently reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, alongside a trading pause on the ASX pending a market-sensitive ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616338779?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-03-02 15:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616338779","market":"us","top_or_hot":-1,"title":"How Investors May Respond To Neuren Pharmaceuticals (ASX:NEU) 2025 Results, Buy-Back Plan And Pipeline Progress","media":"Simply Wall St.","content":"<div>\n<p>Neuren Pharmaceuticals recently reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, alongside a trading pause on the ASX pending a market-sensitive ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-may-respond-to-neuren-pharmaceuticals-asxneu-2\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To Neuren Pharmaceuticals (ASX:NEU) 2025 Results, Buy-Back Plan And Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To Neuren Pharmaceuticals (ASX:NEU) 2025 Results, Buy-Back Plan And Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-02 15:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-may-respond-to-neuren-pharmaceuticals-asxneu-2><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neuren Pharmaceuticals recently reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, alongside a trading pause on the ASX pending a market-sensitive ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-may-respond-to-neuren-pharmaceuticals-asxneu-2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU","symbol_name":"NewMarket","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-may-respond-to-neuren-pharmaceuticals-asxneu-2","article_id":"2616338779","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/how-investors-may-respond-to-neuren-pharmaceuticals-asxneu-2","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616338779","pubTimestamp":1772435590,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Neuren Pharmaceuticals recently reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, alongside a trading pause on the ASX pending a market-sensitive announcement.\nDespite lower year-on-year earnings, Neuren highlighted increased DAYBUE royalties, a new share buy-back program, and progress in its NNZ-2591 pipeline, including an FDA Fast Track designation, underscoring the company’s focus on advancing its rare neurological disorder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEU":"NewMarket","NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK4109":"特种化学制品","BK7508":"医药生物股","ISBC":"投资者银行","BK4211":"区域性银行","BK7096":"制药","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","PRGS":"Progress Software Corporation","BK4097":"系统软件"},"translate_title":"投资者如何应对Neuren Pharmaceuticals(ASX：NEU)2025年业绩、回购计划和管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1.5,"NEU":1.5,"ISBC":1.5,"NEU.AU":1.5},"content_text":"Neuren Pharmaceuticals recently reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, alongside a trading pause on the ASX pending a market-sensitive announcement. Despite lower year-on-year earnings, Neuren highlighted increased DAYBUE royalties, a new share buy-back program, and progress in its NNZ-2591 pipeline, including an FDA Fast Track designation, underscoring the company’s focus on advancing its rare neurological disorder portfolio. We’ll now examine how the new share buy-back program influences Neuren’s existing investment narrative and expectations around future capital needs. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.AdvertisementNeuren Pharmaceuticals Investment Narrative RecapTo own Neuren, you need to believe that DAYBUE royalties can provide a resilient cash engine while NNZ-2591 gradually broadens the rare neurodevelopmental portfolio. The sharp fall in 2025 revenue and earnings, along with the current ASX trading pause, does not yet alter the core near term catalyst around NNZ-2591’s clinical progress, but it does sharpen attention on Neuren’s dependence on Acadia and reimbursement conditions for DAYBUE. The newly announced on-market buy-back of up to 6,350,631 shares (around 5% of issued capital) is the most relevant near term development here. It directly ties the earnings update to capital allocation, reinforcing the existing catalyst of Neuren deploying DAYBUE cash flows while NNZ-2591 advances through Koala Phase 3 and Fast Track, but without resolving the underlying reliance on a single commercial asset. Yet while DAYBUE’s royalties look encouraging, Neuren’s dependence on one marketed drug and evolving reimbursement decisions is something investors should really understand before... Read the full narrative on Neuren Pharmaceuticals (it's free!)Neuren Pharmaceuticals' narrative projects A$166.7 million revenue and A$228.4 million earnings by 2028. This reflects an 8.7% yearly revenue decline but still implies an earnings increase of about A$79.3 million from A$149.1 million today.Uncover how Neuren Pharmaceuticals' forecasts yield a A$23.45 fair value, a 80% upside to its current price.Exploring Other PerspectivesASX:NEU 1-Year Stock Price Chart Some of the more pessimistic analysts were already assuming revenue could shrink to about A$100.7 million and earnings to A$10.7 million, which is far more cautious than the consensus view and the concentration and reimbursement risks you have just read about, so this latest update may prompt you to rethink which storyline you find more convincing.Explore 11 other fair value estimates on Neuren Pharmaceuticals - why the stock might be worth over 7x more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Neuren Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Neuren Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neuren Pharmaceuticals' overall financial health at a glance.No Opportunity In Neuren Pharmaceuticals?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Outshine the giants: these 22 early-stage AI stocks could fund your retirement.AI is about to change healthcare. These 10 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Neuren Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616338779","isCrawlerRequest":true}